Cargando…

Virus-Like Particles Activate Type I Interferon Pathways to Facilitate Post-Exposure Protection against Ebola Virus Infection

Ebola virus (EBOV) causes a severe hemorrhagic disease with high fatality. Virus-like particles (VLPs) are a promising vaccine candidate against EBOV. We recently showed that VLPs protect mice from lethal EBOV infection when given before or after viral infection. To elucidate pathways through which...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ayithan, Natarajan, Bradfute, Steven B., Anthony, Scott M., Stuthman, Kelly S., Bavari, Sina, Bray, Mike, Ozato, Keiko
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2015
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4342244/ https://www.ncbi.nlm.nih.gov/pubmed/25719445 http://dx.doi.org/10.1371/journal.pone.0118345

Ejemplares similares

Mechanisms of Immunity in Post-Exposure Vaccination against Ebola Virus Infection
por: Bradfute, Steven B., et al.
Publicado: (2015)

Ebola Zaire Virus Blocks Type I Interferon Production by Exploiting the Host SUMO Modification Machinery
por: Chang, Tsung-Hsien, et al.
Publicado: (2009)

A STAT-1 knockout mouse model for Machupo virus pathogenesis
por: Bradfute, Steven B, et al.
Publicado: (2011)

Discovering Drugs for the Treatment of Ebola Virus
por: Bixler, Sandra L., et al.
Publicado: (2017)

Clinical Laboratory Values as Early Indicators of Ebola Virus Infection in Nonhuman Primates
por: Reisler, Ronald B., et al.
Publicado: (2017)

Remdesivir is efficacious in rhesus monkeys exposed to aerosolized Ebola virus
por: Warren, Travis K., et al.
Publicado: (2021)

Homologous and Heterologous Protection of Nonhuman Primates by Ebola and Sudan Virus-Like Particles
por: Warfield, Kelly L., et al.
Publicado: (2015)

Therapy of Ebola and Marburg virus infections
por: Bray, Mike
Publicado: (2006)

Interferon-Induced HERC5 Inhibits Ebola Virus Particle Production and Is Antagonized by Ebola Glycoprotein
por: Paparisto, Ermela, et al.
Publicado: (2021)

Toll-Like Receptor Agonist Augments Virus-Like Particle-Mediated Protection from Ebola Virus with Transient Immune Activation
por: Martins, Karen A. O., et al.
Publicado: (2014)

Correlates of Immunity to Filovirus Infection
por: Bradfute, Steven B., et al.
Publicado: (2011)

Histology, immunohistochemistry, and in situ hybridization reveal overlooked Ebola virus target tissues in the Ebola virus disease guinea pig model
por: Cooper, Timothy K., et al.
Publicado: (2018)

Interferon-γ Inhibits Ebola Virus Infection
por: Rhein, Bethany A., et al.
Publicado: (2015)

Reidentification of Ebola Virus E718 and ME as Ebola Virus/H.sapiens-tc/COD/1976/Yambuku-Ecran
por: Kuhn, Jens H., et al.
Publicado: (2014)

Author Correction: Histology, immunohistochemistry, and in situ hybridization reveal overlooked Ebola virus target tissues in the Ebola virus disease guinea pig model
por: Cooper, Timothy K., et al.
Publicado: (2019)

Discovery and Early Development of AVI-7537 and AVI-7288 for the Treatment of Ebola Virus and Marburg Virus Infections
por: Iversen, Patrick L., et al.
Publicado: (2012)

Role of Natural Killer Cells in Innate Protection against Lethal Ebola Virus Infection
por: Warfield, Kelly L., et al.
Publicado: (2004)

Molecular Determinants of Ebola Virus Virulence in Mice
por: Ebihara, Hideki, et al.
Publicado: (2006)

Inhibition of Ebola Virus Entry by a C-peptide Targeted to Endosomes
por: Miller, Emily Happy, et al.
Publicado: (2011)

Gene-Specific Countermeasures against Ebola Virus Based on Antisense Phosphorodiamidate Morpholino Oligomers
por: Warfield, Kelly L, et al.
Publicado: (2006)

Identification of RUVBL1 and RUVBL2 as Novel Cellular Interactors of the Ebola Virus Nucleoprotein
por: Morwitzer, M. Jane, et al.
Publicado: (2019)

Lipid Raft Microdomains: A Gateway for Compartmentalized Trafficking of Ebola and Marburg Viruses
por: Bavari, Sina, et al.
Publicado: (2002)

In Vivo and In Vitro Characterization of Provodine, a Long Acting, Alcohol-Free Professional Antiseptic, Against Ebola Virus and Other Serious Viral, Bacterial and Fungal Pathogens
por: Lentini, Peter, et al.
Publicado: (2015)

Assembly of Ebola Virus Matrix Protein VP40 Is Regulated by Latch-Like Properties of N and C Terminal Tails
por: Silva, Leslie P., et al.
Publicado: (2012)

High Content Image Based Analysis Identifies Cell Cycle Inhibitors as Regulators of Ebola Virus Infection
por: Kota, Krishna P., et al.
Publicado: (2012)

Identification of interferon-stimulated genes that attenuate Ebola virus infection
por: Kuroda, Makoto, et al.
Publicado: (2020)

Ebola Virus Causes Intestinal Tract Architectural Disruption and Bacterial Invasion in Non-Human Primates
por: Reisler, Ronald B., et al.
Publicado: (2018)

Marburg Virus Evades Interferon Responses by a Mechanism Distinct from Ebola Virus
por: Valmas, Charalampos, et al.
Publicado: (2010)

Occupational Exposures to Ebola Virus in Ebola Treatment Center, Conakry, Guinea
por: Savini, Hélène, et al.
Publicado: (2017)

Development of a liquid chromatography high resolution mass spectrometry method for the quantitation of viral envelope glycoprotein in Ebola virus-like particle vaccine preparations
por: Cazares, Lisa H., et al.
Publicado: (2016)

Effective Post-Exposure Treatment of Ebola Infection
por: Feldmann, Heinz, et al.
Publicado: (2007)

Assessing the contribution of interferon antagonism to the virulence of West African Ebola viruses
por: Dunham, Eric C., et al.
Publicado: (2015)

Ebola virus–like particles reprogram cellular metabolism
por: Tang, Huaqi, et al.
Publicado: (2023)

Ebola virus disease
por: Jacob, Shevin T., et al.
Publicado: (2020)

The Ebola Virus Interferon Antagonist VP24 Undergoes Active Nucleocytoplasmic Trafficking
por: Harrison, Angela R., et al.
Publicado: (2021)

Characterization of Ebola Virus Disease (EVD) in Rhesus Monkeys for Development of EVD Therapeutics
por: Warren, Travis, et al.
Publicado: (2020)

Approach to Cataract Surgery in an Ebola Virus Disease Survivor with Prior Ocular Viral Persistence
por: Wells, Jill R., et al.
Publicado: (2020)

Virus-Like Particle Vaccination Protects Nonhuman Primates from Lethal Aerosol Exposure with Marburgvirus (VLP Vaccination Protects Macaques against Aerosol Challenges)
por: Dye, John M., et al.
Publicado: (2016)

Identification of Novel Adjuvants for Ebola Virus-Like Particle Vaccine
por: Feng, Huapeng, et al.
Publicado: (2020)

The FDA-Approved Oral Drug Nitazoxanide Amplifies Host Antiviral Responses and Inhibits Ebola Virus
por: Jasenosky, Luke D., et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_hom3jg41j3tcruglovgivdod34